Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 801–900 of 1,003
Appetite-related Gut Hormone Responses to Feeding Across the Life Course
Holliday, A., Horner, K. M., Johnson, K. O., Dagbasi, A., & Crabtree, D. R. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae223 · Cited by 26
A prospective study of appetite and food craving in 30 patients with Cushing’s disease
Geer, E. B., Lalazar, Y., Couto, L., Cohen, V. V., Lipton, L. R., Shi, W., Bagiella, E., Conwell, I. M., Bederson, J. B., Kostadinov, J., et al. (2015) · Pituitary · doi:10.1007/s11102-015-0690-1 · Cited by 26
English, P., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison, J., Eccleston, D., Bloom, S. R., Ghatei, M. A., & Wilding, J. P. H. (2006) · Diabetologia · doi:10.1007/s00125-006-0344-y · Cited by 25
“Fasting concentrations are lower and postprandial responses attenuated in obese subjects [3], and infusions of PYY to mimic the postprandial concentrations found in lean subjects reduce appetite and food intake in obese subjects [3, 4], suggesting a potential role in the pathogenesis of obesity.”
BackgroundSelf-citationHankir, M. K., Parkinson, J. R. C., MINNION, J. S., Addison, M., Bloom, S. R., & Bell, J. D. (2011) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02111.x · Cited by 24
Self-citationPeripheral mechanisms in the control of appetite and related experimental therapies in obesity
Camilleri, M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.04.011 · Cited by 23
“After the demonstrations that PYY retards gastric emptying of a liquid meal [4], reduces calorie intake and feeling of hunger [32], and administration of PYY3–36 reduced calorie intake in lean and obese participants [18], there was considerable interest in the potential for Camilleri Page 3”
BackgroundResultA Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY3–36
Addison, M., MINNION, J. S., Shillito, J. C., Suzuki, K., Tan, T., Field, B. C. T., Germain-Zito, N., Becker‐Pauly, C., Ghatei, M. A., Bloom, S. R., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1195 · Cited by 24
Self-citationPostpyloric Gastrointestinal Peptides
Gomez, G. A., Englander, E. W., & Greeley, G. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00007-5 · Cited by 24
Half-Life Extending Modifications of Peptide YY3–36 Direct Receptor-Mediated Internalization
Bech, E. M., Kaiser, A., Bellmann‐Sickert, K., Bohr, S. S.-R., Sørensen, K. K., Elster, L., Hatzakis, N. S., Pedersen, S. L., Beck‐Sickinger, A. G., & Jensen, K. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00554 · Cited by 24
Regulatory effects of Y4 receptor agonist (BVD-74D) on food intake
Li, J.-B., Asakawa, A., Terashi, M., Cheng, K., Chaolu, H., Zoshiki, T., Ushikai, M., Sheriff, S., Balasubramaniam, A., & Inui, A. (2010) · Peptides · doi:10.1016/j.peptides.2010.06.011 · Cited by 27
A cellular basis for heightened gut sensitivity in females
Venkataraman, A., Figueroa, E. E., Castro, J., Navarro, F., Soota, D., Brierley, S. M., Julius, D. J., & Ingraham, H. A. (2025) · Science · doi:10.1126/science.adz1398 · Cited by 24
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 26
Guerrero, S., Agüı́, L., Yáñez‐Sedeño, P., & Pingarrón, J. M. (2018) · Talanta · doi:10.1016/j.talanta.2018.09.089 · Cited by 22
The significance and potential of functional food ingredients for control appetite and food intake
Esmaeili, M., Ajami, M., Barati, M., Javanmardi, F., Houshiarrad, A., & Khaneghah, A. M. (2022) · Food Science & Nutrition · doi:10.1002/fsn3.2783 · Cited by 24
Rubinić, I., Kurtov, M., & Likić, R. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1243 · Cited by 27
Fat-Rich Food Palatability and Appetite Regulation
Erlanson‐Albertsson, C. (2009) · Frontiers in neuroscience · doi:10.1201/9781420067767-c14 · Cited by 24
Macronutrient Regulation of Ghrelin and Peptide YY in Pediatric Obesity and Prader-Willi Syndrome
Balikcioglu, P. G., Balikcioglu, M., Muehlbauer, M. J., Purnell, J. Q., Broadhurst, D., Freemark, M., & Haqq, A. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2503 · Cited by 24
“In contrast with ghrelin, a gastric hormone that promotes food intake, PYY is produced by intestinal L cells and inhibits food intake (28).”
BackgroundPatel, S., Mace, O. J., Tough, I. R., White, J. R., Cock, T., Berglund, U. W., Schindler, M., & Cox, H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.10 · Cited by 24
Gut–brain cross-talk in appetite regulation
Cegla, J., Tan, T., & Bloom, S. R. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833b64a3 · Cited by 25
Self-citationChoi, Y., Hur, C., & Park, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056610 · Cited by 22
“Recently, plasma Pyy concentrations were found to be decreased in both obese humans [52] and diet-induced obese mice [53].”
BackgroundVos, R. C., Wit, J. M., Pijl, H., Kruyff, C. C., & Houdijk, E. C. A. M. (2011) · Trials · doi:10.1186/1745-6215-12-110 · Cited by 26
“Abbreviations BMI: Body Mass Index; BMI-SDS: Body Mass Index Standard Deviation Score; CBCL: Child Behavior Checklist; CBSK: Perceived Competence Scale for Children (CompetentieBelevingsSchaal voor Kinderen); CRP: C-Reactive Protein; GLP-1: Glucagon-like peptide 1; HDL-cholesterol: High Density Lipoprotein Cholesterol…”
BackgroundInfluentialNeuropeptide receptors as potential pharmacological targets for obesity
Meneguetti, B. T., Cardoso, M. H. E. S., Ribeiro, C. F. A., Felício, M. R., Pinto, I. B., Santos, N. C., Carvalho, C. M. E., & Franco, O. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.002 · Cited by 26
CCK1 Antagonists: Are They Ready for Clinical Use?
Peter, S. A. S., D’Amato, M., & Beglinger, C. (2006) · Digestive Diseases · doi:10.1159/000090310 · Cited by 22
“] have studied the role of the CCK antagonist loxiglumide in the treatment of chronic constipation due to non-IBS. In a randomized, placebo-controlled, double-blind study, 18 geriatric patients were treated with a 3-week period of loxiglumide or placebo. Loxiglumide increased the stool frequency and led to a decrease…”
BackgroundPeptide YY Levels across Pubertal Stages and Associations with Growth Hormone
Lloyd, B., Ravi, P. K., Mendes, N., Klibanski, A., & Misra, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2496 · Cited by 22
“J Clin Endocrinol Metab, June 2010, 95(6):2957–2962 jcem.”
BackgroundInfluentialPhylogeny of NPY-Family Peptides and Their Receptors
Larhammar, D., Fredriksson, R., Larson, E. T., & Salaneck, E. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18764-3_4 · Cited by 25
“As PYY has been found to act as an inhibitor of feeding ( Batterham et al. 2002, 2003a ), it is interesting to note that also PP has been found to have such effects in rat and mouse (Asakawa et al. 2003) as well as in humans (Batterham et al. 2003b) and patients with the Prader-Willi syndrome (Bernston et al. 1993).”
Teegarden, D., & Gunther, C. W. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2008.00111.x · Cited by 23
Oertel, M., Ziegler, C. G., Kohlhaas, M., Nickel, A. G., Kloock, S., Maack, C., Sequeira, V., Faßnacht, M., & Dischinger, U. (2024) · Endocrine Connections · doi:10.1530/ec-23-0398 · Cited by 25
“Exogenous PYY3-36 infusions reduce food intake and increase energy expenditure in lean and obese humans (31, 32).”
BackgroundThe vagus nerve mediates the physiological but not pharmacological effects of PYY3-36 on food intake
Alonso, A. M., Cork, S. C., Phuah, P., Hansen, B., Norton, M., Cheng, S., Xu, X., Suba, K., Ma, Y., Dowsett, G. K. C., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101895 · Cited by 22
“PYY 3-36 retains its anorectic effects in obese subjects [6], suggesting potential utility as an anti-obesity pharmacotherapy.”
BackgroundSelf-citationAppetite and Hedonism: Gut Hormones and the Brain
Simpson, K. A., & Bloom, S. R. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.08.001 · Cited by 26
Self-citationAmini, P., Cahill, F., Wadden, D., Ji, Y., Pedram, P., Vidyasankar, S., Yi, Y., Gulliver, W. P., Paterno, G. D., Zhang, H., et al. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-35 · Cited by 21
“Ghrelin is a 28 amino acid appetite stimulant peptide secreted primarily from the stomach, and PYY is an appetite suppressant hormone secreted from the enteroendocrine cells of the ileum and colon [6-8].”
BackgroundThe effects of food components on hormonal signalling in gastrointestinal enteroendocrine cells
Bruen, C. M., O’Halloran, F., Cashman, K. D., & Giblin, L. (2012) · Food & Function · doi:10.1039/c2fo30086a · Cited by 28
Hormonal regulation of appetite
Bloom, S. R. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00320.x · Cited by 26
“Orlistat (Xenical) impairs fat absorption from the gut and is advised for subjects who can demonstrate weight loss by diet alone prior to taking it (2,3).”
BackgroundSelf-citationGavrieli, A., & Mantzoros, C. S. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.3.361 · Cited by 22
Physiologic and Neural Controls of Eating
Moran, T. H., & Ladenheim, E. E. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.07.009 · Cited by 26
Pork, beef and chicken have similar effects on acute satiety and hormonal markers of appetite
Charlton, K. E., Tapsell, L. C., Batterham, M. J., Thorne, R., O’Shea, J. E., Zhang, Q., & Beck, E. J. (2010) · Appetite · doi:10.1016/j.appet.2010.10.013 · Cited by 25
Hypothalamic Injection of Oxyntomodulin Suppresses Circulating Ghrelin-Like Immunoreactivity
Patterson, M., Murphy, K. G., Patel, S. R., Patel, N. A., Greenwood, H. C., Cooke, J. H., Campbell, D., Bewick, G. A., Ghatei, M. A., & Bloom, S. R. (2009) · Endocrinology · doi:10.1210/en.2008-0796 · Cited by 21
“humans (17, 18), whereas others have observed a similar effect”
Self-citationEffects of resistance exercise and obesity level on ghrelin and cortisol in men
Thomas, G. A., Kraemer, W. J., Comstock, B. A., Dunn‐Lewis, C., Volek, J. S., Denegar, C. R., & Maresh, C. M. (2011) · Metabolism · doi:10.1016/j.metabol.2011.10.015 · Cited by 24
“Ghrelin levels are low in simple obesity and are negatively correlated to percentage body fat, but increase with weight loss [16-18].”
BackgroundPhysiological endocrine control of energy homeostasis and postprandial blood glucose levels.
Gagliardino, J. J. (2005) · PubMed · Cited by 31
Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake
Elliott, J. A., Reynolds, J. V., le Roux, C. W., & Docherty, N. G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1245140 · Cited by 22
“weight subjects [210], although at present no published study has demonstrated weight loss in response to chronic administration in man.”
BackgroundJin, Z., Li, J., Thackray, A. E., Shen, T., Deighton, K., King, J. A., & Stensel, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01726-4 · Cited by 20
“4 RCTs [45, 50, 52, 54] were included in the meta-analysis, comprising 8 independent groups across the studies (1 CR; 6 EX; 1 CREX), and involving 233 participants (SI3 - Figure S11).”
Physiological Appetite Regulation and Bariatric Surgery
Ramasamy, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051347 · Cited by 27
“Intravenous PYY 3–36 decreased appetite in both healthy and obese subjects [108].”
BackgroundLu, C., An, X., Yu, Y., Jiao, L.-R., Canarutto, D., Li, G., & Yu, G. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.08.006 · Cited by 22
Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
Holst, J. J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.964406 · Cited by 21
Boix-Castejón, M., Roche, E., Olivares-Vicente, M., Álvarez-Martínez, F. J., Herranz‐López, M., & Micol, V. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154735 · Cited by 24
Scott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 20
Self-citationStress inhibits PYY secretion in obese and normal weight women
Kiessl, G. R. R., & Laessle, R. G. (2015) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-015-0231-y · Cited by 24
He, J., Votruba, S. B., Pomeroy, J. J., Bonfiglio, S. M., & Krakoff, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036225 · Cited by 22
“In mice and human studies, exogenous peripheral or central administration of insulin, leptin, PYY, and GLP-1 reduced food intake by acting as a meal ending satiety signal [24–27].”
BackgroundEmerging drugs for obesity therapy
Zanella, M. T., & Filho, F. F. R. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000200019 · Cited by 26
Current knowledge in the neurophysiologic modulation of obesity
Angelopoulos, N., Goula, A., & Tolis, G. (2005) · Metabolism · doi:10.1016/j.metabol.2005.04.005 · Cited by 23
“Endogenous PYY levels are low in obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity [166].”
BackgroundInfluentialKamiji, M. M., Troncon, L. E. A., Antunes‐Rodrigues, J., Elias, L. L. K., de Castro, M., & de Oliveira, R. B. (2010) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2010.88 · Cited by 20
“PYY3 36 is a hormone produced by the L cells of the distal gastrointestinal tract (Batterham et al., 2003).”
BackgroundCloning and characterization of a zebrafish Y2 receptor
Fredriksson, R., Sjödin, P., Larson, E. T., Conlon, J. M., & Larhammar, D. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2005.09.013 · Cited by 20
The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
Melvin, A., le Roux, C. W., & Docherty, N. G. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0599-9 · Cited by 24
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 154
A case of severe anorexia, excessive weight loss and high peptide YY levels after sleeve gastrectomy
Pucci, A. B. F., Cheung, W. H., Jones, J., Manning, S., Kingett, H., Adamo, M., Elkalaawy, M., Jenkinson, A. D., Finer, N., Doyle, J., et al. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-15-0020 · Cited by 21
Self-citationLas hormonas gastrointestinales en el control de la ingesta de alimentos
Álvarez-Crespo, M., González-Matías, L. C., Gil‐Lozano, M., Paz, S. F., Romaní‐Pérez, M., Gago, E. M., & Ferrer, F. M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)71946-1 · Cited by 30
Peptide YY (3–36) inhibits dopamine and norepinephrine release in the hypothalamus
Brunetti, L., Orlando, G., Ferrante, C., Chiavaroli, A., & Vacca, M. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.07.008 · Cited by 20
Field, B. C. T. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu001 · Cited by 23
The Maintenance of Energy Balance Is Compromised after Weight Loss
Reed, J. L., Chaput, J., Tremblay, A., & Doucet, É. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.03.022 · Cited by 22
The role of gut hormones in controlling the food intake. What is their role in emerging diseases?
Prete, A. D., Iadevaia, M. D., & Loguercio, C. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.11.007 · Cited by 22
Rigamonti, A. E., Cella, S. G., Bonomo, S., Mancia, G., Grassi, G. M., Perotti, M., Agosti, F., Sartório, A., Müller, E. E., & Pincelli, A. I. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0312 · Cited by 19
Ahmad, M. A., Karavetian, M., Moubareck, C. A., Wazz, G., Mahdy, T., & Venema, K. (2022) · Nutrients · doi:10.3390/nu14061271 · Cited by 22
“It is highly plausible that, in contrast to other peptide hormones, obesity is not associated with resistance to PYY, thus explaining the lack of difference in its fasting concentrations between lean and obese individuals [53,54].”
BackgroundKacinik, V., Lyon, M. R., Purnama, M., Reimer, R. A., Gahler, R. J., Green, T., & Wood, S. (2011) · Nutrition and Diabetes · doi:10.1038/nutd.2011.18 · Cited by 21
Damgaard, M., Graff, J., Fuglsang, S., Holst, J. J., Rehfeld, J. F., & Madsen, J. L. (2012) · e-SPEN Journal · doi:10.1016/j.clnme.2012.10.004 · Cited by 19
Yuzuriha, H., Inui, A., Asakawa, A., Ueno, N., Kasuga, M., Meguid, M. M., Miyazaki, J., Ninomiya, M., Herzog, H., & Fujimiya, M. (2007) · The FASEB Journal · doi:10.1096/fj.06-7621com · Cited by 19
Lean and obese dietary phenotypes: differences in energy and substrate metabolism and appetite
Clamp, L. D., Hehir, A. P. J., Lambert, E. V., Beglinger, C., & Goedecke, J. H. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515003402 · Cited by 20
“In contrast, PYY, a short-term satiation hormone, produced mainly by distal-intestinal L cells in response to a meal, is lower in obese individuals((23)).”
BackgroundAbnormalities of the somatotrophic axis in the obese agouti mouse
Martin, N. M., Houston, P. A., Patterson, M., Sajedi, A., Carmignac, D. F., Ghatei, M. A., Bloom, S. R., & Small, C. J. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803076 · Cited by 21
Self-citationGhrelin: A Link between Eating Disorders, Obesity and Reproduction
Gottero, C., Broglio, F., Prodam, F., Destefanis, S., Bellone, S., Benso, A. S., Gauna, C., Arvat, E., van der Lely, A. J., & Ghigo, E. (2004) · Nutritional Neuroscience · doi:10.1080/10284150400017363 · Cited by 19
“Moreover, in further agreement with the major role of metabolic and nutritional factors in the regulation of ghrelin secretion, it has also been reported that several factors involved in the regulation of food intake and metabolic balance are also able to inhibit ghrelin secretion such as Glucagon-like peptide 1 (Lipp…”
BackgroundGuerrero, S., García, G. M., Serafín, V., Agüı́, L., Yáñez‐Sedeño, P., & Pingarrón, J. M. (2015) · The Analyst · doi:10.1039/c5an01185j · Cited by 18
Lueders, B., Kanney, B. C., Krone, M. J., Gannon, N. P., & Vaughan, R. A. (2022) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2022.200168 · Cited by 19
Identification of selective neuropeptide Y2 peptide agonists
DeCarr, L. B., Buckholz, T. M., Coish, P., Fathi, Z., Fisk, S. E., Mays, M. R., O'Connor, S. J. M., & Lumb, K. J. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.007 · Cited by 18
Interaction of Dietary composition and PYY gene expression in diet-induced obesity in rats
Nianhong, Y., Chongjian, W., Xu, M., Mao, L., Liu, L., & Xiufa, S. (2005) · Current Medical Science · doi:10.1007/bf02828131 · Cited by 18
Kim, H. H. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i30.4044 · Cited by 18
Psychiatric Issues in Bariatric Surgery
Norris, L. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.07.011 · Cited by 18
Franklin, Z. J., Tsakmaki, A., Pedro, P. F., King, A., Huang, G. C., Amjad, S., Persaud, S. J., & Bewick, G. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13119 · Cited by 19
“A and B, Anti-apoptotic properties of PYY(1-36).”
MethodGuglielmo, M. D. D., Tonb, D., He, Z., Adeyemi, A., & van Golen, K. L. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001796 · Cited by 19
“Levels peak after 15 minutes and plateau by 90 minutes as noted in animal studies (11); in human studies 1 to 2 hours is noted as peak rise (11).”
PYY is a negative regulator of bone mass and strength
Leitch, V. D., Brassill, M. J., Rahman, S. A., Butterfield, N. C., Ma, P., Logan, J. G., BOYDE, A., Evans, H., Croucher, P. I., Batterham, R. L., et al. (2019) · Bone · doi:10.1016/j.bone.2019.07.011 · Cited by 21
“Systemic PYY levels are low in the fasted state and increase in response to nutrient ingestion [10,14,15].”
BackgroundSelf-citationPedersen, S. L., Holst, B., Vrang, N., & Jensen, K. J. (2009) · Journal of Peptide Science · doi:10.1002/psc.1170 · Cited by 18
Obesity and Its Therapy: From Genes to Community Action
Skelton, J. A., DeMattia, L., Miller, L. A., & Olivier, M. (2006) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2006.05.011 · Cited by 30
“Peptide YY (PYY) is an enteric-derived hormone that was identified in studies of rodents [57,58].”
BackgroundPossible involvement of food texture in insulin resistance and energy metabolism in male rats
Bae, C., Hasegawa, K., Akieda‐Asai, S., Kawasaki, Y., Senba, K., Cha, Y., & Date, Y. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0553 · Cited by 19
“The initial increase is thought to be induced via neural or endocrine mechanisms (Batterham et al. 2003), and the sustained release is thought to be due to the direct effects of the gut contents on PYY-producing cells mainly located in the lower intestine (Imamura 2002).”
BackgroundGhrelin secretion in humans – a role for the vagus nerve?
Veedfald, S., Plamboeck, A., Hartmann, B., Vilsbøll, T., Knop, F. K., Deacon, C. F., Svendsen, L. B., & Holst, J. J. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13295 · Cited by 18
Shih, P.-A. B., Wang, L., Chiron, S., Wen, G., Nievergelt, C. M., Mahata, M., Khandrika, S., Rao, F., Fung, M. M., Mahata, S. K., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0465 · Cited by 23
Food Addiction and Cues in Prader-Willi Syndrome
von Deneen, K. M., Gold, M. S., & Liu, Y. (2009) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31819a6e5f · Cited by 17
Behary, P., Cegla, J., Tan, T., & Bloom, S. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1048181 · Cited by 20
“These hormones have been shown to induce satiety, promote insulin release, and increase energy expenditure in humans [59-63].”
BackgroundSelf-citationRational Development of Stable PYY3–36 Peptide Y2 Receptor Agonists
Poulsen, C., Pedersen, M. Ø., Wahlund, P., Sjölander, A., Thomsen, J. K., Conde‐Frieboes, K. W., Paulsson, J. F., Wulff, B. S., & Østergaard, S. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03077-x · Cited by 18
Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction
Reddy, Y. N. V., Melenovský, V., Asokan, A. K., Haluzı́k, M., Carter, R. E., Nair, K. S., Jensen, M. D., & Borlaug, B. A. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae534 · Cited by 17
Effects of gastric bypass bariatric surgery on gut microbiota in patients with morbid obesity
Amin, U., Huang, D. C., Dhir, A., Shindler, A. E., Franks, A. E., & Thomas, C. J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2427312 · Cited by 17
Fuller, N. R., Lau, N. S., Denyer, G. S., & Caterson, I. D. (2013) · Clinical Obesity · doi:10.1111/cob.12030 · Cited by 20
“However, the secretion of PYY occurs shortly after food intake (20,38), thus having a larger contribution in the postprandial response to a meal.”
BackgroundThe Effect of an Egg Breakfast on Satiety in Children and Adolescents: A Randomized Crossover Trial
Liu, A. G., Puyau, R. S., Han, H., Johnson, W. D., Greenway, F. L., & Dhurandhar, N. V. (2015) · Journal of the American College of Nutrition · doi:10.1080/07315724.2014.942471 · Cited by 22
“There is evidence in both adults and children that suggests that appetite hormones are less responsive to meal feeding in obese subjects [18,32,33].”
BackgroundImpact of restraint and disinhibition on PYY plasma levels and subjective feelings of appetite
Martins, C., Robertson, M. D., & Morgan, L. (2010) · Appetite · doi:10.1016/j.appet.2010.05.091 · Cited by 17
“Exogenous administration of physiological doses of PYY has been shown to reduced appetite and foodconsumptionby30%comparedwithsaline infusion (Batterham et al., 2003).”
BackgroundNeff, L. M., & Aronne, L. J. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0061-0 · Cited by 22
“Intravenous administration of exogenous PYY in both overweight and normal-weight subjects has been shown to decrease fasting ghrelin concentration and reduce food intake by more than 25% for up to 12 hours [ 53 ].”
BackgroundInfluence of diabetes surgery on gut hormones and incretins.
Papamargaritis, D., Miras, A. D., & le Roux, C. W. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6719 · Cited by 24
Central Modulation of Energy Homeostasis and Cognitive Performance After Bariatric Surgery
Eickhoff, H. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-63260-5_9 · Cited by 18
Merkel, R., Moreno, A., Zhang, Y., Herman, R. J., Nathan, J. B., Zeb, S., Rahematpura, S., Stecyk, K. S., Milliken, B. T., Hayes, M. R., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.026 · Cited by 17
New agents in development for the management of obesity
Vincent, R. P., & le Roux, C. W. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01558.x · Cited by 18
Huang, X., Yu, Y., Li, Y., South, T., Deng, C., & Wang, Q. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9661-5 · Cited by 19
“In both humans and mice, plasma PYY concentration has been found to be lower in obese compared to lean subjects after fasting or an immediate bout of refeeding [40, 41 ].”
BackgroundInteractions of Gastrointestinal Peptides: Ghrelin and Its Anorexigenic Antagonists
Wisser, A.-S., Habbel, P., Wiedenmann, B., Klapp, B. F., Mönnikes, H., & Kobelt, P. (2010) · International Journal of Peptides · doi:10.1155/2010/817457 · Cited by 22
“However, recent data are conflicting as one study showed PYY infusion to significantly reduces plasma ghrelin levels in humans [93] while other reports failed to find an influence on ghrelin concentrations in mice [94] and pigs [95].”
ResultInfluence of Hormonal Appetite and Energy Regulators on Bone
Khor, E. C., Wee, N. K. Y., & Baldock, P. A. J. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0157-0 · Cited by 21
“In obese patients, as determined by a high BMI, basal PYY levels are generally decreased in comparison with the control patients whilst an increase BMD is observed [34–36].”
Kojima, S., Tohei, A., & Anzai, N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02094.x · Cited by 20
“PYY is an anorectic gut hormone; circulating levels of PYY are low in the fasted state but are high in the fed state, and postprandial plasma PYY concentrations remain elevated for several hours (Adrian et al., 1985; Batterham et al., 2003).”
BackgroundInfluentialY1 receptor deficiency in β-cells leads to increased adiposity and impaired glucose metabolism
Loh, K., Shi, Y., Bensellam, M., Lee, K., Laybutt, D. R., & Herzog, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-30140-2 · Cited by 20
An investigation of the neural mechanisms underlying the efficacy of the adjustable gastric band
Stefanidis, A., Forrest, N., Brown, W. A., Dixon, J. B., O’Brien, P. B., Kampe, J., & Oldfield, B. J. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.11.020 · Cited by 17
Friis-Hansen, L. J., Wierup, N., Rehfeld, J. F., & Sundler, F. (2005) · Endocrinology · doi:10.1210/en.2004-0938 · Cited by 18
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.